4th Quarter - Report

APOTEX CORP. for APOTEX CORP.

Firm
Client
Income
—
Expenses
$220,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

FDA proposed rule, Supplemental Applications Proposing Labeling Changes For Approved Drugs And Biological Products, Docket Number FDA-2013-N-0500, provisions relating to generic drug labeling changes; Federal policy relating to issues affecting the generic drug industry within the House Energy and Commerce Committee's 21st Century Cures initiative; Federal policy relating to International Nonproprietary Names for Biosimilars; HR 5657, the Fair Access for Safe and Effective Generics Act, provisions relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing; HR 5748/S 2948, the Medicaid Generic Drug Fairness Act, provisions relating to Medicaid rebates for generic pharmaceuticals; Federal policy relating to the use of generic drugs in the Medicare Part D program; Federal policy relating to the implementation of the Biologic Price Competition and Innovation Act, Title VII, Subtitle A, of Public Law 111-148, the Patient Protection and Affordable Care Act; and HR 3116, the MODDERN Cures Act, provisions relating to the exclusivity term for dormant therapies

Foreign entity interest: Aposherm Inc., Apotex Holdings Inc., Sherfam Inc., and Shermco Inc., the parent companies of Apotex Corp. identified on LD-1, have direct or indirect interests in companies that develop, manufacture, and/or sell generic drugs and therefore are interested in the issues identified in this report.

LobbyistCovered position, as disclosed
STEVEN GIULI —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 3116 (113th), H.R. 5657 (113th), H.R. 5748 (113th)

Trade (domestic/foreign) TRD

Federal policy relating to legal remedies for pharmaceutical companies in the Trans Pacific Partnership trade negotiations

Foreign entity interest: Aposherm Inc., Apotex Holdings Inc., Sherfam Inc., and Shermco Inc., the parent companies of Apotex Corp. identified on LD-1, have direct or indirect interests in companies that develop, manufacture, and/or sell generic drugs and therefore are interested in the issues identified in this report.

LobbyistCovered position, as disclosed
STEVEN GIULI —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.